What is it about?
By limiting H19 gene function using drugs that are already used to treat cancer, therapy-resistant breast cancer tumours become sensitive to anti estrogen drugs such as Tamoxifen, Fluvestrant and Aromatase inhibitors.
Featured Image
Why is it important?
Although, current drugs to treat estrogen hormone dependent breast cancer tumors are effective, yet many patients develop resistance to such anti estrogen therapies. This results in tumour recurrence, spread of tumour to other parts of the patient's body. Unfortunately once the tumor reaches this stage there are very limited therapy options available to the patients. Our work describes how to make therapy resistant tumor sensitive to conventional approved therapies and therefore limiting tumor recurrence and spread.
Perspectives
It is hoped that our work would inspire clinical trials to examine if our discovery can be used to improve treatment of recurrent therapy resistant breast cancer tumors.
afshin raouf
University of Manitoba
Read the Original
This page is a summary of: Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells, Cellular Physiology and Biochemistry, January 2018, Karger Publishers,
DOI: 10.1159/000495643.
You can read the full text:
Contributors
The following have contributed to this page
